Bond University Research Repository



Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis

Marx, Wolfgang; Lane, Melissa; Rocks, Tetyana; Ruusunen, Anu; Loughman, Amy; Lopresti, Adrian; Marshall, Skye; Berk, Michael; Jacka, Felice; Dean, Olivia May

Published in: Nutrition Reviews

DOI: 10.1093/nutrit/nuz023

Licence: Other

Link to output in Bond University research repository.

Recommended citation(APA): Marx, W., Lane, M., Rocks, T., Ruusunen, A., Loughman, A., Lopresti, A., Marshall, S., Berk, M., Jacka, F., & Dean, O. M. (2019). Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis. *Nutrition Reviews*, *77*(8), 557-571. Article nuz023. https://doi.org/10.1093/nutrit/nuz023

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository coordinator.

1	The effect of saffron supplementation on symptoms of depression and anxiety: a
2	systematic review and meta-analysis
3	Article type: Special article
4	Wolfgang Marx ¹ *, Melissa Lane ¹ , Tetyana Rocks ¹ , Anu Ruusunen ^{1,2,3} , Amy Loughman ¹ ,
5	Adrian Lopresti ⁴ , Skye Marshall ⁵ , Michael Berk ^{6,7} , Felice Jacka ^{1,8,9^} , Olivia M. Dean ^{6,10,11^}
6	*Corresponding author: wolf.marx@deakin.edu.au
7	Post address: Food & Mood Centre, 285 Ryrie Street, 3220, Victoria, Australia
8	^ Co-senior author
9	Affiliations
10	1. Deakin University, Food & Mood Centre, IMPACT SRC, School of Medicine,
11	Geelong, Australia.
12	2. Department of Psychiatry, Kuopio University Hospital, Kuopio, Finland
13	3. Institute of Public Health and Clinical Nutrition, University of Eastern Finland,
14	Kuopio, Finland
15	4. School of Psychology and Exercise Science, Murdoch University, Perth, Western
16	Australia, Australia
17	5. Faculty of Health Sciences & Medicine, Bond University, Robina, Queensland,
18	Australia
19	6. Deakin University, IMPACT SRC, School of Medicine, Barwon Health, Geelong
20	Australia.
21	7. Department of Psychiatry; Orygen, the National Centre of Excellence in Youth
22	Mental Health; Centre for Youth Mental Health and the Florey Institute for
23	Neuroscience and Mental Health, University of Melbourne, Australia

- 8. Centre for Adolescent Health, Murdoch Children's Research Institute, VIC; Australia
 9. Black Dog Institute, NSW; Australia
 10. Florey Institute for Neuroscience and Mental Health, University of Melbourne, Kenneth Myer Building, 30 Royal Parade, 3052, Parkville, Australia.
 11. University of Melbourne, Department of Psychiatry, Level 1 North, Main Block,
- 29 Royal Melbourne Hospital, Parkville, 3052, Australia

1 Abstract

Context

Saffron (Crocus sativus L.) has gained interest as a potential treatment in psychiatry.

Objective

To investigate the effect of saffron supplementation, as both an adjunctive and monotherapy, on symptoms of depression and anxiety in clinical and general populations compared with pharmacotherapy or placebo.

Data sources

Using the PRISMA guidelines, a systematic literature review of randomized controlled trials was conducted.

Data extraction

A meta-analysis was conducted to determine treatment effect. Risk of bias was assessed using the Jadad scale.

Data Analysis

Twenty-three studies were included. Saffron had a large positive effect size when compared to placebo for depressive symptoms (g=0.99, p<0.001) and anxiety symptoms (g=0.95, p<0.006). Saffron also had a large positive effect size when used as an adjunct to antidepressants for depressive symptoms (g=1.23, p=0.028). Egger's regression test found evidence of publication bias.

Conclusions

Saffron could be an effective intervention for symptoms of depression and anxiety. However, due to evidence of publication bias and lack of regional diversity, further trials are required. PROSPERO registration #CRD42017070060.

Keywords: saffron, herbal medicine, depression, mood disorder, nutraceutical, mental health, inflammation, treatment.

1 2 Introduction

2 Saffron (Crocus sativus L.) and its constituents including, crocin, crocetin, and safranal may have a positive effect on several neurobiological mechanisms implicated in mental illness ¹⁻³. 3 4 In animal models, whole saffron and implicated compounds have been reported to modulate 5 pathways related to neurotransmitters, immune regulation, inflammation, oxidative stress, hypothalamus-pituitary-adrenal (HPA) axis, and neurotrophins ⁴. For example, in rats, the 6 7 administration of a saffron extract dose-dependently increased brain concentrations of dopamine and, at high doses, increased glutamate levels ⁵. In another study, the 8 9 administration of crocin modulated serotonergic activity in rats exposed to the non-selective 10 serotonin receptor agonist meta-chlorophenylpiperazine, lowering obsessive-like behaviours 11 ⁶. Saffron constituents also have anti-inflammatory, immune regulating, and antioxidant properties, including the modulation of endogenous antioxidant enzymes ⁷⁻¹¹. In addition, 12 13 studies using animal stress models have confirmed that saffron modulates HPA axis activity by reducing plasma corticosterone concentrations ^{12,13}. Finally, support for the 14 neuroprotective effects of saffron and its constituent, crocin, is derived from studies 15 16 demonstrating positive effects on the neurotrophin, brain-derived neurotrophic factor (BDNF) in animal stress models ^{14,15}. 17

Two previous meta-analyses have reported saffron supplementation to improve measures of depression in clinical trials ^{16,17}. Previous meta-analyses on this topic, however, have only examined effects of saffron on depression in clinical populations with mild to major depression ^{16,17}. Furthermore, since the publication of these reviews, several published intervention studies have been conducted both in depression and in other mental illnesses. Therefore, using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, this systematic review and meta-analysis of randomized, controlled

trials (RCTs) aims to examine the transdiagnostic effects of saffron supplementation (as a stand-alone or adjunctive intervention) on symptoms of mental illness in both clinical and general populations compared with pharmacotherapy or placebo.

28

29 3 Methods

30 3.1 Literature search

This review was written in accordance with the PRISMA (Supplementary Material 1)¹⁸ and 31 32 was prospectively registered on PROSPERO (CRD42017070060). A search strategy was 33 developed based on the research question (Table 1). Studies were identified using the following databases: Medline (Pubmed), PsychInfo, Embase, The Cochrane Library, and 34 35 CINAHL. Search terms were related to saffron and its constituents ("saffron" OR "crocus" 36 OR "crocin" OR "crocetin") and mental health outcomes ("depression" OR "depressive disorder" OR "anxiety disorders" OR "affective symptoms" OR anxi* OR mood OR 37 "psychological symptoms" OR "psychological distress"). The search strategy identified 38 39 articles published since journal inception up to March 2018. 40 Studies were required to be RCTs including cross-over studies; published in English, 41 included measures of mental health (e.g. depression, low mood, depressive symptoms, 42 emotional problems, and anxiety), and used any component of saffron (e.g. whole saffron, 43 standardized extracts, parts of saffron or specific saffron-derived compounds). Interventions 44 that included saffron in combination with standard medications were included; however, 45 combined interventions with other novel ingredients were excluded. No limit on age or population was included and the comparator could be either placebo or pharmacotherapy. 46

47 3.2 Data extraction

Two authors (ML and AL) independently screened individual studies in duplicate with 48 49 disagreements resolved by consensus or third author (WM). Using a standardized and piloted 50 extraction form, the following parameters were extracted from included studies: author/date, 51 study design, sample size, total study period, population characteristics (including age, 52 gender, and co-morbidities), intervention characteristics (including dose, type, and duration of exposure, concomitant treatment), length of follow up, adverse events, and mental health-53 related outcomes including measures of depression, anxiety, mood. Outcomes not related to 54 55 mental health were not extracted for this review.

56 3.3 Assessment of study risk of bias

Risk of bias was assessed using the Jadad scale, a five-item tool that assesses risk of bias due
to randomization, blinding, and follow up ¹⁹. Studies can receive a score between zero and
five, with a higher score indicating a lower risk of bias.

60 3.4 Statistical Analyses

The meta-analyses were conducted in Comprehensive Meta-Analysis 3.0^{20} using a 61 DerSimonian-Laird random-effects model²¹ to account for heterogeneity between studies. 62 The primary outcome was the effect of saffron on total depressive symptoms in comparison 63 64 to placebo control conditions. The effect of saffron on symptoms of depression as an 65 adjunctive to medication and as a stand-alone intervention compared to medication was also computed as a secondary outcome. The effect of saffron on symptoms of anxiety compared to 66 67 placebo, medication and as an adjunctive intervention were also computed when sufficient data were available. Mean change scores in symptoms for saffron and control conditions were 68 69 compared using random-effects meta-analyses to compute effect size of saffron compared to

6

70 control condition as Hedges' g (with 95% confidence intervals (CI)). For studies that used 71 more than one measure of the same outcome, the measure identified as the primary outcome 72 by the respective study was used in meta-analyses. Otherwise, an average change score 73 across all measures was computed and used in the pooled analysis. In multi-arm trials that 74 had more than one active saffron condition, a pooled effect was computed across all saffron arms compared to the non-saffron comparator conditions. To examine the possibility of 75 76 publication bias affecting results, Eggers' t-test was conducted. Finally, to further account for 77 the potential impact of publication bias, a Duval and Tweedie's trim-and-fill analysis was 78 applied to in order to recalculate effect sizes after statistically accounting for outlier studies. 79 Additionally, subgroup analyses were conducted to examine the (i) effects of saffron in 80 comparison to antidepressant medications, and (ii) the effect of saffron on depression when 81 used as an adjunctive treatment alongside antidepressants (i.e. studies comparing saffron to 82 placebo in samples already taking, or commencing, antidepressant medications). 83 Heterogeneity between studies was examined using Cochran's Q (with p-value) and I² 84 estimates. These statistics estimate the extent to which statistical heterogeneity between 85 studies has arisen from genuine inter-study differences, rather than due to chance.

86 4 Results

87 4.1 Study selection

As represented in Figure 1, the search strategy resulted in 310 de-duplicated studies that were
screened to identify 23 eligible studies for inclusion (see Table 2).

90 4.2 Study Characteristics

A total of 1237 participants were enrolled in the included studies, with 30 to 128 participants
in each study. Trials ran from 4 to 12 weeks with 6 weeks being the most common trial

93 length (9/23). Seventeen studies investigated saffron monotherapy (n=11 studies) or as an adjunctive pharmacotherapy compared to placebo (n=6 studies). Six studies compared saffron 94 monotherapy to an antidepressant medication (including fluoxetine,²²⁻²⁵ imipramine,²⁶ and 95 citalopram²⁷). No study investigated saffron as an adjunct to psychotherapy. Nineteen studies 96 97 included participants with either clinical diagnosis of mental illness or had clinical symptoms 98 of mental illness using a validated tool. The average age of participants was 39 years with a 99 range of 14 to 57 years. Most studies included a mix of genders with 5 studies including only 100 females and 1 study including only males. Most studies were conducted in Iran (21/23) with two studies conducted in Australia^{28,29}. Thirteen studies were conducted by the same 101 102 research group. Risk of bias across most studies was low with 20 studies receiving a score 103 between 4 and 5 (out of 5) on the Jadad Scale (Supplementary Material 2).

104 4.3 Interventions

Most studies (19/23) used a dose of 30 mg per day of saffron. Ten studies used the stigma of saffron, 4 studies used saffron petals, 3 used crocin only, and the remaining studies used either a whole powder or did not provide further details. Nine studies reported that the intervention was standardized to contain either crocin, safranal, or lepticrosalides[®] (a measure of bioactive compounds present in saffron, including safranal and crocin isomers).

110 4.4 Outcome measures

- 111 Depressive symptoms (22/23) were more commonly investigated than anxiety symptoms
- 112 (8/23). Depression and/or anxiety symptoms were measured using either the Hamilton Rating
- 113 Scale for Depression or Anxiety, Beck Depression Inventory, Depression Anxiety Stress
- 114 Scale (DASS) 21, or Revised Child Anxiety and Depression Scale (RCADS; youth and
- 115 parent versions). One study assessed mood using the Profile of Mood States (POMS) and
- 116 Positive and Negative Affect Schedule (PANAS) 21 tools.

117 4.5 Study Results

118 4.5.1 Effects of Saffron on Depressive Symptoms

119 Random-effects meta-analysis found a significant and large positive effect size for saffron 120 reducing symptoms of depression in comparison to placebo (g=0.99, 95% CI=0.61 to 1.37, n=14 studies, n=716 participants, p < 0.001; Figure 2). An additional study that could not be 121 122 entered into the meta-analysis due to insufficient available data also reported saffron to significantly improve depressive symptoms compared to placebo³⁰. There was significant 123 124 heterogeneity across the study data (Q=71.8, p<0.001, I²=81.9%). Egger's regression test found strong evidence of publication bias (Intercept=6.99, p=0.007). The funnel plot of 125 126 publication bias is displayed in Supplementary Material 3. Correcting for publication bias 127 using a trim-and-fill analysis increased the effect size of saffron supplementation (g=1.14, 128 95% CI=0.74 to 1.52).

129 When compared to antidepressants medications, there was no significant difference between

130 saffron and medications (g=-0.17, 95% CI=0.50 to 0.17, n=5 studies, n=210 participants,

131 p=0.33; Figure 2). There was a low degree of heterogeneity across the study data (Q=6.16,

132 $p=0.19, I^2=35.1\%$). One study that did not report sufficient information to be included in the

133 meta-analysis also reported no significant difference in depressive symptoms between saffron

- 134 and medication 23 .
- 135 Meta-analysis of studies that investigated the effect of saffron as an adjunct to
- 136 pharmacotherapy (i.e. in studies comparing saffron to placebo in people taking
- 137 antidepressants) reported a large significant benefit from saffron supplementation (n=4 trials,

138 n=144 participants, g=1.23, 95% CI=0.13 to 2.33, p=0.028, Q=27.62, $I^2 = 89.1\%$). One study

139 that could not be included in the meta-analysis reported no significant difference in

9

- depressive symptoms between the adjunctive group (fluoxetine and saffron) and control
 (fluoxetine and placebo) ³¹.
- 142 4.5.2 Effects of Saffron on Symptoms of Anxiety

143 Figure 3 displays the effects of saffron mono and adjunctive therapy on symptoms of anxiety 144 across 6 RCTs compared to placebo (n=375 participants). Random-effects meta-analysis 145 found a large positive effect size for saffron on reducing symptoms of anxiety in comparison 146 to placebo control conditions (g=0.95, 95% CI=0.27 to 1.63, p<0.006). There was significant heterogeneity across the study data (Q=44.38, p<0.001, I² =88.74%). Egger's regression test 147 148 found strong evidence of publication bias (Intercept=0.12, p=0.028). Correcting for 149 publication bias using a trim-and-fill analysis increased the effect size of saffron 150 supplementation (g=1.40, 95% CI=0.60 to 2.150). There were insufficient studies to conduct 151 a meta-analysis of the effect of saffron on anxiety in comparison to antidepressant 152 medications or to conduct subgroup analysis of saffron as an adjunctive treatment. One study 153 that investigated the effect of saffron for anxiety symptoms compared to citalopram reported no significant difference between treatment groups ²⁷. 154

155 4.5.3 Sensitivity Analyses

156 Sensitivity analyses were performed to exclude one outlier study that could be influencing the

157 overall findings ³². Exclusion of this study only slightly reduced the overall effect size of

- 158 saffron on depressive symptoms compared to placebo (g=0.84, 95% CI=0.53 to 1.16,
- 159 p<0.001), although large heterogeneity (Q=45.45, p<0.001, I^2 =73.8%) and significant
- 160 publication bias was still evident in the remaining 13 studies (Eggers regression intercept =

161 4.957, *p*=0.043).

When performing sensitivity analyses with the outlier study excluded for anxiety outcomes,the effects of saffron compared to placebo were reduced substantially, although overall

results remained the same (g=0.48, 95% CI=0.25 to 0.70, p<0.001). There was also little indication of heterogeneity (Q=3.39, p=0.50, $I^2=0\%$) or publication bias (Eggers regression intercept = 0.23, p=0.47) in the remaining 5 studies, although this is likely due to standard tests for detecting heterogeneity/publication bias in meta-analysis being underpowered in this small a number of studies.

169 4.5.4 Effects of Saffron on Additional Outcomes

170 One study reported a significant improvement in total score of mood disturbances (p < 0.001)

171 and subscales of fatigue (p=0.007), tension (p=0.025), vigour (p=0.007), confusion

172 (p=0.001), negative affect (p=0.001), and stress (p<0.001) when saffron supplementation was

173 compared to placebo ²⁸. Another study reported significant improvements in self-reported

174 measures of internalising symptoms (p=0.049), separation anxiety (p=0.003), and social

175 phobia (p=0.023) compared to placebo ²⁹. General mental health was improved in one study

176 compared to placebo $(p < 0.001)^{32}$ and the emotional functioning subscale of a quality of life

177 questionnaire also improved in a separate study after saffron supplementation compared to 178 placebo (p < 0.001)³³.

179 4.6 Adverse events

180 Most studies (21/23) reported on adverse events. Headache, nausea, anxiety, constipation, dry 181 mouth, and appetite changes were the most commonly reported symptoms in both arms. No 182 study reported symptoms occurring in the saffron group at a statistically higher rate compared 183 to both placebo and medication.

184 **5** Discussion

185 This is the most comprehensive meta-analysis to evaluate the effects of saffron

186 supplementation for depressive and anxiety symptoms. Together, the inclusion of adult,

adolescent, and sub-clinical depressive and anxiety populations, as well as the examination of
both depression and anxiety outcomes, provides a greater understanding of the possible
efficacy of saffron as an intervention across the common mental disorders.

190 The results of this meta-analysis are consistent with two prior meta-analyses that investigated saffron for mild-to-major depression only ^{16,17}. Saffron had a significant large positive effect 191 size when compared to placebo for both depression and anxiety outcomes. For depressive 192 193 outcomes, saffron also had a significant large positive effect size when used as an adjunctive 194 treatment to antidepressants and when compared against antidepressant medications, there 195 was no significant difference between groups. The included studies demonstrate that saffron 196 supplementation appears to be well-tolerated with few adverse events being reported within the included studies or by other authors ³⁴. However, all studies to date have been of 197 198 relatively short duration and with a limited sample size. Therefore, longer-term trials that are 199 suitably powered are required to assess the safety of saffron supplementation.

200 In the context of standard interventions for depression and anxiety, the results from the 201 placebo-controlled trials, suggest an effect size that is considerably greater than standard 202 pharmacotherapy, such as selective serotonin reuptake inhibitors (Cohen's d=0.30)³⁵. 203 However, the five trials directly comparing saffron to antidepressant medication reported no 204 statistically significant difference (p=0.33). Due to the large effect sizes, the significant 205 publication bias detected for both outcomes, and the majority of trials being conducted in one 206 region, many by the same research group (13/23), there is a need to replicate these results 207 within other populations and in large, well-powered, rigorous trials before clinical 208 recommendations are justified. Similarly, greater rigour regarding Good Manufacturing 209 Practice and standardization, dosage and characterization of the active ingredients is needed.

210 In addition to the need to replicate existing studies, there are additional areas recommended 211 for future studies. First, the use of saffron for other mental illnesses is currently 212 underexplored. While seven studies assessed anxiety symptoms, only one study included 213 participants with a diagnosed anxiety disorder. Similarly, one study evaluated the safety and feasibility of saffron in schizophrenia, but no efficacy trials have been conducted to date ³⁶. 214 215 Furthermore, there is a need to explore comparative efficacy of the different components of saffron. One study reported that saffron petal and stigma had equivalent efficacy in treating 216 217 depressive symptoms in participants with major depression but there is insufficient literature to comment on particular components at this stage ³⁷. Due to the high cost of saffron for 218 219 culinary use, previous reviews have recommended the investigation of the efficacy of less 220 expensive parts of saffron (e.g. petal and corm)⁴. However, due to the small therapeutic 221 dosage used in current studies, the cost of saffron formulations is unlikely to be considerably higher than for other nutraceutical interventions. 222

223 Preclinical studies suggest that compounds contained within saffron have a range of potentially relevant mechanisms of action including antioxidant, anti-inflammatory properties 224 and are able to modulate BDNF expression and the HPA-axis⁴. However, these pathways 225 226 have been largely unexplored within clinical trials. Hence, there is a need to measure markers 227 of relevant pathways within future clinical trials to explore the association between changes 228 of these biological markers and clinical symptoms. Furthermore, as demonstrated by Rapaport et al.³⁸, who reported that treatment response to omega-3 (eicosapentaenoic acid) 229 230 was greater in those with higher inflammation at baseline, measuring relevant biomarkers 231 may provide valuable information regarding specific populations and participant stratification 232 to determine who is likely to respond to saffron treatment. Related to this is the need for 233 dose-finding studies to establish the optimal dosing regimen. Most studies have used 30mg

per day of saffron; however, it is unclear if there are other regimens that may improve thetherapeutic effect.

236 6 Conclusion

237 In summary, the existing evidence suggests a potential for saffron to be an efficacious 238 intervention for symptoms of depression and anxiety. However, the strength of this 239 conclusion is moderated by the lack of large-scale trials, and significant risk of publication 240 bias among the many small- scale pilot trials published on this topic. Indeed, the large effect 241 sizes reported in some studies require replication in further clinical trials that address 242 methodological limitations and the lack of regional diversity before clinical recommendations 243 can be made. Trials that explore the mechanisms of action of saffron, dosage, active 244 ingredients, long-term safety, as well as the efficacy in diagnosed mental illnesses are also 245 required.

246 7 Acknowledgments

247 We would like to acknowledge Dr Joe Firth and Professor Jerome Sarris for their contribution

on aspects of the analyses and interpretation for the initial version of the manuscript. OMD

249 would like to acknowledge the support of the National Health and Medical Research Council

250 for providing a Career Development (2) Fellowship (APP1145634).

251 8 Funding declaration

252 No funding was provided for the development of this manuscript. WM is supported by a

253 Deakin University research fellowship. **TR** is supported by a Fernwood Foundation

Fellowship. AR is supported by a Deakin University research fellowship. AL is supported by

the Wilson Foundation. **MB** is supported by a National Health and Medical Research Council

256 (NHMRC) Senior Principal Research Fellowship (grant number 1059660). FNJ has received

14

257 Grant/Research support from the Brain and Behaviour Research Institute, the National Health and Medical Research Council (NHMRC), Australian Rotary Health, the Geelong Medical 258 259 Research Foundation, the Ian Potter Foundation, Eli Lilly, Meat and Livestock Australia, 260 Woolworths Limited, Fernwood Gyms, The Wilson Foundation, GMHBA and The 261 University of Melbourne and has received speakers honoraria from Sanofi-Synthelabo, 262 Janssen Cilag, Servier, Pfizer, Health Ed, Network Nutrition, Angelini Farmaceutica, Eli 263 Lilly and Metagenics. FNJ is supported by an NHMRC Career Development Fellowship (2) 264 (#1108125). FNJ is currently writing two books for commercial publication and has a 265 personal belief that good diet quality is important for mental and brain health. OMD is a R.D. 266 Wright Biomedical Research Fellow and has received grant support from the Brain and 267 Behavior Foundation, Simons Autism Foundation, Stanley Medical Research Institute, 268 Deakin University, Lilly, NHMRC and ASBDD/Servier. She has also received in kind 269 support from BioMedica Nutracuticals, NutritionCare and Bioceuticals. 270 **Author Contributions** 271 All authors contributed to final manuscript. WM led all stages of the manuscript. ML and AL

272 conducted the data extraction. SM conduct the risk of bias assessment. TR, ML and AR

extracted the data from included studies. ALopresti contributed to the mechanisms discussion

and background.

275

References

- 1. Maes M, Leonard B, Fernandez A, et al. (Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: from antioxidants to kinase inhibitors. *Progress in Neuro-psychopharmacology & Biological Psychiatry*. 2011;35(3):659-663.
- 2. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. *Nat Rev Immunol.* 2015;16(1):22-34.
- 3. Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. *Molecular psychiatry.* 2013;18(5):595-606.
- 4. Lopresti AL, Drummond PD. Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action. *Hum Psychopharmacol.* 2014;29(6):517-527.
- 5. Ettehadi H, Mojabi SN, Ranjbaran M, et al. Aqueous Extract of Saffron (Crocus sativus) Increases Brain Dopamine and Glutamate Concentrations in Rats. *Journal of Behavioral and Brain Science.* 2013;3(3):315-319.
- 6. Georgiadou G, Tarantilis PA, Pitsikas N. Effects of the active constituents of Crocus Sativus L., crocins, in an animal model of obsessive-compulsive disorder. *Neuroscience letters*. 2012;528(1):27-30.
- 7. Razavi M, Hosseinzadeh H, Abnous K, Motamedshariaty VS, Imenshahidi M. Crocin restores hypotensive effect of subchronic administration of diazinon in rats. *Iran J Basic Med Sci.* 2013;16(1):64-72.
- 8. Boskabady MH, Farkhondeh T. Antiinflammatory, Antioxidant, and Immunomodulatory Effects of Crocus sativus L. and its Main Constituents. *Phytother Res.* 2016;30(7):1072-1094.
- 9. Samarghandian S, Nezhad MA, Samini F, Farkhondeh T. The role of saffron in attenuating agerelated oxidative damage in rat hippocampus. *Recent Pat Food Nutr Agric.* 2017.
- 10. Poma A, Fontecchio G, Carlucci G, Chichiricco G. Anti-inflammatory properties of drugs from saffron crocus. *Anti-inflammatory & anti-allergy agents in medicinal chemistry*. 2012;11(1):37-51.
- 11. Boskabady MH, Seyedhosseini Tamijani SM, Rafatpanah H, Rezaei A, Alavinejad A. The effect of Crocus sativus extract on human lymphocytes' cytokines and T helper 2/T helper 1 balance. *Journal of medicinal food.* 2011;14(12):1538-1545.
- 12. Halataei BA, Khosravi M, Arbabian S, et al. Saffron (Crocus sativus) aqueous extract and its constituent crocin reduces stress-induced anorexia in mice. *Phytotherapy research : PTR*. 2011;25(12):1833-1838.
- 13. Hooshmandi Z, Rohani AH, Eidi A, Fatahi Z, Golmanesh L, Sahraei H. Reduction of metabolic and behavioral signs of acute stress in male Wistar rats by saffron water extract and its constituent safranal. *Pharmaceutical biology*. 2011;49(9):947-954.
- 14. Vahdati Hassani F, Naseri V, Razavi BM, Mehri S, Abnous K, Hosseinzadeh H. Antidepressant effects of crocin and its effects on transcript and protein levels of CREB, BDNF, and VGF in rat hippocampus. *Daru.* 2014;22(1):16.
- 15. Ghasemi T, Abnous K, Vahdati F, Mehri S, Razavi BM, Hosseinzadeh H. Antidepressant Effect of Crocus sativus Aqueous Extract and its Effect on CREB, BDNF, and VGF Transcript and Protein Levels in Rat Hippocampus. *Drug Res (Stuttg).* 2014. http://www.ncbi.nlm.nih.gov/pubmed/24696423. Accessed Apr 2.
- 16. Hausenblas HA, Saha D, Dubyak PJ, Anton SD. Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials. *Journal of integrative medicine*. 2013;11(6):377-383.

- 17. Yang X, Chen X, Fu Y, et al. Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials. *Neuropsychiatr Dis Treat.* 2018;14:1297-1305.
- 18. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. *PLOS Medicine*. 2009;6(7):e1000100.
- 19. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Controlled clinical trials*. 1996;17(1):1-12.
- 20. *Comprehensive meta-analysis version 3* [computer program]. Englewood, NJ: Biostat 104 2011.
- 21. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Controlled clinical trials.* 1986;7(3):177-188.
- 22. Akhondzadeh Basti A, Moshiri E, Noorbala AA, Jamshidi AH, Abbasi SH, Akhondzadeh S. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: A pilot double-blind randomized trial. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2007;31(2):439-442.
- 23. Kashani L, Eslatmanesh S, Saedi N, et al. Comparison of Saffron versus Fluoxetine in Treatment of Mild to Moderate Postpartum Depression: A Double-Blind, Randomized Clinical Trial. *Pharmacopsychiatry*. 2017;50(2):64-68.
- 24. Noorbala A, Akhondzadeh S, Tahmacebi-Pour N, Jamshidi A. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. *Journal of ethnopharmacology*. 2005;97(2):281-284. http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/149/CN-00508149/frame.html.
- 25. Shahmansouri N, Farokhnia M, Abbasi S, et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients. *Journal of affective disorders.* 2014;155:216-222. http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/884/CN-00959884/frame.html.
- 26. Akhondzadeh S, Fallah-Pour H, Afkham K, Jamshidi AH, Khalighi-Cigaroudi F. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816]. *BMC complementary and alternative medicine*. 2004;4 (no pagination)(12).
- 27. Ghajar A, Neishabouri SM, Velayati N, et al. Crocus sativus L versus Citalopram in the Treatment of Major Depressive Disorder with Anxious Distress: A Double-Blind, Controlled Clinical Trial. *Pharmacopsychiatry*. 2017;50(4):152-160.
- 28. Kell G, Beccaria G, Rao A, Clayton P, Inarejos-García AM, Prodanov M. affron[®] a novel saffron extract (Crocus sativus L.) improves mood in healthy adults over 4 weeks in a double-blind, parallel, randomized, placebo-controlled clinical trial. *Complementary Therapies in Medicine*. 2017;33:58-64.
- 29. Lopresti AL, Drummond PD, Inarejos-Garcia AM, Prodanov M. affron((R)), a standardised extract from saffron (Crocus sativus L.) for the treatment of youth anxiety and depressive symptoms: A randomised, double-blind, placebo-controlled study. *Journal of affective disorders.* 2018;232:349-357.
- 30. Tabeshpour J, Sobhani F, Sadjadi SA, et al. A double-blind, randomized, placebo-controlled trial of saffron stigma (Crocus sativus L.) in mothers suffering from mild-to-moderate postpartum depression. *Phytomedicine*. 2017;36:145-152.
- 31. Sahraian A, Jelodar S, Javid Z, Mowla A, Ahmadzadeh L. Study the effects of saffron on depression and lipid profiles: A double blind comparative study. *Asian Journal of Psychiatry*. 2016;22:174-176.

- 32. Talaei A, Hassanpour Moghadam M, Sajadi Tabassi SA, Mohajeri SA. Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: A randomized, double-blind, placebo-controlled, pilot clinical trial. Journal of affective disorders. 2015;174:51-56.
- 33. Abedimanesh N, Ostadrahimi A, Bathaie SZ, et al. Effects of saffron aqueous extract and its main constituent, crocin, on health-related quality of life, depression, and sexual desire in coronary artery disease patients: A double-blind, placebo-controlled, randomized clinical trial. Iranian Red Crescent Medical Journal. 2017;19 (9) (no pagination)(e13676).
- 34. Modaghegh MH, Shahabian M, Esmaeili HA, Rajbai O, Hosseinzadeh H. Safety evaluation of saffron (Crocus sativus) tablets in healthy volunteers. *Phytomedicine*. 2008;15(12):1032-1037.
- 35. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet (London, England). 2018;391(10128):1357-1366.
- 36. Moosavi S, Ahmadi M, Amini M, Vazirzadeh B. The effects of 40 and 80 mg hydro- alcoholic extract of crocus sativus in the treatment of mild to moderate depression. Journal of medical 2014;24(113):47-53. mazandaran university of sciences. http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/117/CN-00999117/frame.html.
- 37. Akhondzadeh Basti A, Moshiri E, Noorbala AA, Jamshidi AH, Abbasi SH, Akhondzadeh S. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Progress in neuro-psychopharmacology & *biological psychiatry.* 2007;31(2):439-442.
- 38. Rapaport MH, Nierenberg AA, Schettler PJ, et al. Inflammation as a Predictive Biomarker for Response to Omega-3 Fatty Acids in Major Depressive Disorder: A Proof of Concept Study. Molecular psychiatry. 2016;21(1):71-79.
- 39. Akhondzadeh S, Tahmacebi-Pour N, Noorbala A, et al. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. *Phytotherapy Research.* 2005;19(2):148-151.
- 40. Agha-Hosseini M, Kashani L, Aleyaseen A, et al. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. BJOG : an international journal of obstetrics and gynaecology. 2008;115(4):515-519.
- 41. Jafarnia N, Ghorbani Z, Nokhostin M, Manayi A, Nourimajd S, Jahromi SR. Effect of saffron (Crocus sativus L.) as an add-on therapy to sertraline in mild to moderate generalized anxiety disorder: A double blind randomized controlled trial. Archives of Neuroscience. 2017;4 (4) (no pagination)(e14332).
- 42. Jam IN, Sahebkar AH, Eslami S, et al. The effects of crocin on the symptoms of depression in subjects with metabolic syndrome. Advances in Clinical and Experimental Medicine. 2017;26(6):925-930.
- 43. Jelodar G, Javid Z, Sahraian A, Jelodar S. Saffron improved depression and reduced homocysteine level in patients with major depression: A Randomized, double-blind study. Avicenna Journal of Phytomedicine. 2018;8(1):43-50.
- 44. Kashani L, Esalatmanesh S, Eftekhari F, et al. Efficacy of Crocus sativus (saffron) in treatment of major depressive disorder associated with post-menopausal hot flashes: a double-blind, randomized, placebo-controlled trial. Archives of Gynecology and Obstetrics. 2018;297(3):717-724.
- 45. Kashani L, Raisi F, Saroukhani S, et al. Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study. Human psychopharmacology. 2013;28(1):54-60.

http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/835/CN-00861835/frame.html.

- 46. Mazidi M, Shemshian M, Mousavi SH, et al. A double-blind, randomized and placebocontrolled trial of Saffron (Crocus sativus L.) in the treatment of anxiety and depression. *Journal of Complementary and Integrative Medicine*. 2016;13(2):195-199.
- 47. Moazen-Zadeh E, Abbasi SH, Safi-Aghdam H, et al. Effects of Saffron on Cognition, Anxiety, and Depression in Patients Undergoing Coronary Artery Bypass Grafting: A Randomized Double-Blind Placebo-Controlled Trial. *Journal of alternative and complementary medicine (New York, NY).* 2017.
- Modabbernia A, Sohrabi H, Nasehi A, et al. Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial. *Psychopharmacology*. 2012;223(4):381-388. <u>http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/596/CN-00850596/frame.html</u>.
- 49. Moshiri E, Basti A, Noorbala A, Jamshidi A, Hesameddin AS, Akhondzadeh S. Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebo-controlled trial. *Phytomedicine*. 2006;13(9-10):607-611. http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/244/CN-00572244/frame.html.

Figure 1. PRISMA flow chart of study selection

Figure 2. Meta-analysis showing effects of saffron on symptoms of depression in (a) comparison to antidepressant medications, and (b) comparison to placebo controls. Box size represents study weighting. Diamond represents overall effect size and 95% confidence intervals.

Figure 3. Meta-analysis of the effects of saffron on symptoms of anxiety. Box size represents study weighting. Diamond represents overall effect size and 95% confidence intervals.

Supplementary Information

Supplement 1. PRISMA Checklist

Supplement 2. Risk of bias summaries for included studies.

Supplement 3. Forest-plot of publication bias

Table 1. PICOS criteria for inclusion and exclusion of

studies

Domain	Criteria
Population	Human participants, both clinically diagnosed with a mental illness and otherwise
Intervention	Saffron supplementation. Both whole saffron or as an extract
Comparator	Placebo or standard antidepressant medication
Outcomes	Symptoms of mental illness, adverse events

Table 2. Summary table of included studies

Author/ Date	Study details	Population details	Intervention (mgs per	Outcomes*	Results
			day)		
Abedimanesh	Study design:	Male and female Coronary	30 mg	Outcomes measured:	The BDI-II score
et al. (2017) ³³	Randomized, double blind,	Artery Disease (CAD)	SAE, Saffron Aqueous	Depression measured using	significantly decreased in
	placebo controlled	patients	Extract (stigma)	BDI-II	the SAE and Crocin groups
	Country: Iran	Age in years (average): 55	OR 30 mg	Outcomes measured at:	compared to Placebo from
	Sample size (n): 63		Crocin (stigma)	Baseline and after 8 weeks	baseline to endpoint (<i>P</i> < 0.001). No significant
	enrolled, 58 completed			of intervention	difference between the
	Total study period: 8		OR Placebo		Crocin and SAE groups in
	weeks				total BDI-II score at
					endpoint ($P = 0.999$).
Akhondzadeh	Study design:	Male and female	30 mg Saffron (petal) OR	Outcomes measured:	The HAM-D-17 score
Basti et al.	Randomized, double blind,	outpatients who met DSM-	20 mg Fluoxetine	Depression measured using	significantly decreased in
$(2007)^{22}$	parallel group	IV criteria for major		HAM-D-17	both the Saffron and
					Fluoxetine groups from

This is a pre-copyedited, author-produced version of an article accepted for publication in Nutrition Reviews following peer review. The version of record Marx, W., Lane, M., Rocks, T., Ruusunen, A., Loughman, A., Lopresti, A., ... Dean, O. M. (2019). Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis. Nutrition Reviews, [nuz023] is available online at: <u>https://doi.org/10.1093/nutrit/nuz023</u>.

	Country: Iran	depression based on the		Outcomes measured at:	baseline to endpoint ($P <$
	Sample size: 40 enrolled,	SCID-IV		Baseline, week 1, week 2,	0.001). No significant
	38 completed	Age in years (average): 34		week 4, week 6 and week 8	difference at endpoint
	-			(endpoint)	between the two groups (P
	Total study period: 8				= 0.84).
	weeks				
Akhondzadeh	Study design:	Male and female	30 mg Saffron (stigma) OR	Outcomes measured:	The HAM-D-17 score
et al. (2005) ³⁹	Randomized, double blind,	outpatients who met DSM-	Placebo	Depression measured using	significantly decreased in
	parallel group	IV criteria for major		HAM-D-17	both the Saffron and
	Country: Iran	depression based on the			Placebo groups from
		SCID-IV		Outcomes measured at:	baseline to endpoint ($P <$
	Sample size: 40 enrolled,	Age in years (average): 36		Baseline, week 1, week 2,	0.001). However, the
	35 completed	Age in years (average). 50		week 4 and week 6	Saffron group had
	Total study period: 6			(endpoint)	significantly lower HAM-
	weeks				D-17 scores at endpoint
					compared to Placebo ($P <$
					0.001).

Akhondzadeh	Study design:	Male and female	30 mg Saffron (stigma) OR	Outcomes measured:	The HAM-D-17 score
et al. (2004) ²⁶	Randomized, double blind,	outpatients who met DSM-	100 mg Imipramine	Depression measured using	significantly decreased in
	parallel group	IV criteria for major		HAM-D-17	both the Saffron and
	Country: Iran	depression based on the			Imipramine groups from
		SCID-IV		Outcomes measured at:	baseline to endpoint ($P <$
	Sample size: 30 enrolled,	Age in years (average): 34		Baseline, week 1, week 2,	0.001). No significant
	30 completed	rige in years (average). 5 f		week 3, week 4, week 5 and	difference at endpoint
	Total study period: 6			week 6 (endpoint)	between the two groups (P
	weeks				= 0.09).
		XX7 1.1 1			
Agha-	Study design:	Women with regular	30 mg Saffron (petal) OR	Outcomes measured:	The HAM-D-17 score
Hosseini et al.	Randomized, double blind,	menstrual cycles and	Placebo	Depression measured using	significantly decreased in
(2008) ⁴⁰	placebo controlled	experience of PMS		HAM-D-17	the Saffron group compared
	Country: Iran	symptoms for at least 6			to Placebo from baseline to
	Country. Indi	months		PMS factors including	endpoint (<i>P</i> < 0.001).
	Sample size: 50 enrolled,	Age in years (average): 34		mood (e.g. anxiety,	
	47 completed			irritability, depression,	The total Daily Symptom
				nervous tension, mood	Report Checklist score
					significantly decreased in

	Total study period: 8			swings and out of control)	the Saffron group compared
	weeks; or two menstrual			measured using	to Placebo from baseline to
	cycles (cycles 3 and 4)			Daily Symptom Report Checklist	endpoint, ($P = 0.002$).
				Outcomes measured at:	
				Baseline (i.e. at the end of	
				cycle 2, a premenstrual	
				stage—as close as possible	
				to 2 days prior to the onset	
				of menstruation) and the	
				premenstrual stage of	
				cycles 3 and 4.	
Ghajar et al.	Study design:	Male and female patients	30 mg Saffron (stigma) OR	Outcomes measured:	The HAM-D-17 and HAM-
(2017) ²⁷	Randomized, double blind,	who met DSM-IV criteria	40 mg Citalopram	Depression measured using	A scores significantly
	parallel group	for mild-to-moderate major		HAM-D-17	decreased in both the
	Country: Iran	depression coupled with			Saffron and Citalopram
		anxious distress			groups from baseline to

	Sample size: 66 enrolled,	Age in years (average): 36		Anxiety measured using	endpoint ($P < 0.001$). No
	60 completed			HAM-A	significant difference for
	Total study period: 6			Outcomes measured at:	either HAM-D-17 or HAM-
	weeks			Baseline, week 2, week 4	A scores at endpoint
				and week 6 (endpoint)	between the two groups (P
					0.715 and $P = 0.999$,
					respectively).
Jafarnia et al.	Study design:	Male and female patients	500 mg capsule containing	Outcomes measured:	The HAM-A score
(2017) ⁴¹	Randomized, double blind,	who met DSM-IV criteria	450 mg Saffron (type not	Anxiety measured using	significantly decreased in
	placebo controlled	for mild-to-moderate	recorded) AND 50 mg	HAM-A	both the Saffron (coupled
	Country: Iran	Generalised Anxiety	Sertraline OR Placebo		with Sertraline) and
		Disorder (GAD) and were	AND 50 mg Sertraline	Outcomes measured at:	Placebo (coupled with
	Sample size: 40 enrolled,	receiving Sertraline		Baseline, week 3 and week	Sertraline) groups from
	40 completed	Age in years (average): 31		6 (endpoint)	baseline to endpoint ($P <$
	Total study period: 6	inge in years (average). 31			0.000). However, the
	weeks				Saffron (coupled with
					Sertraline) group had
					significantly lower HAM-A

1 -

26


This is a pre-copyedited, author-produced version of an article accepted for publication in Nutrition Reviews following peer review. The version of record Marx, W., Lane, M., Rocks, T., Ruusunen, A., Loughman, A., Lopresti, A., ... Dean, O. M. (2019). Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis. Nutrition Reviews, [nuz023] is available online at: <u>https://doi.org/10.1093/nutrit/nuz023</u>.


					scores at endpoint
					compared to Placebo
					(coupled with Sertraline),
					(<i>P</i> < 0.005).
Jam et al.	Study design:	Male and female patients	30 mg Saffron (crocin) OR	Outcomes measured:	The BDI score significantly
(2017) ⁴²	Randomized, double blind,	with Metabolic Syndrome	Placebo	Depression measured using	decreased in the Saffron
	placebo controlled	(MetS) and depressive		BDI	group but not in the Placebo
	Country: Iran	symptoms based on the			group from baseline to
	·	BDI		Outcomes measured at:	endpoint ($P < 0.005$ and P
	Sample size: 34 enrolled,	A go in woons (overlage), 46		Baseline and week 8	> 0.05, respectively).
	33 completed	Age in years (average): 46		(endpoint)	Significant difference at
	Total study period: 8				endpoint between the two
	weeks				groups ($P = 0.013$).
Jelodar et al.	Study design:	Male and female	30 mg Saffron (stigma)	Outcomes measured:	The BDI score significantly
(2018) ⁴³	Randomized, double blind,	outpatients who met DSM-	AND 20 mg Fluoxetine OR	Depression measured using	decreased in both the
	placebo controlled	IV criteria for major	Placebo AND 20 mg	BDI	Saffron (coupled with
	Country: Iran		Fluoxetine		Fluoxetine) and Placebo

	Sample size: 40 enrolled,	depression based on the		Outcomes measured at:	(coupled with Fluoxetine)
	40 completed	SCID-IV		Baseline and week 4	groups from baseline to
	Total study period: 4	Age in years (range): 20 to		(endpoint)	endpoint ($P < 0.05$). No significant difference at
	weeks	55			endpoint between the two groups ($P < 0.056$).
Kashani et al. (2018) ⁴⁴	Study design: Randomized, double blind, placebo controlled	Women who met DSM-IV criteria for major depression and mild-to-	30 mg Saffron (stigma) OR Placebo	Outcomes measured: Depression measured using HDRS	The HDRS score significantly decreased in both Saffron and Placebo
	Country: Iran Sample size: 60 enrolled, 56 completed Total study period: 6	moderate depression based on HDRS as well as post- menopausal hot flashes Age in years (average): 55		Outcomes measured at: Baseline, week 2, week 4 and week 6 (endpoint)	groups from baseline to endpoint ($P < 0.01$). However, the Saffron group had significantly lower HDRS scores at endpoint
	weeks				compared to Placebo (<i>P</i> < 0.001).

Kashani et al.	Study design:	Women who met DSM-IV	30 mg Saffron (stigma) OR	Outcomes measured:	*Significance of reduction
$(2017)^{23}$	Randomized, double blind,	criteria for post-partum	20 mg Fluoxetine	Depression measured using	in HDRS score within
	parallel group	depression 4-12 weeks after		HDRS	groups for Saffron and
	Country: Iran Sample size: 68 enrolled,	childbirth as well as scoring > 10 and < 18 on HDRS		Outcomes measured at: Baseline, week 1, week 3	Fluoxetine from baseline to endpoint not recorded.
	64 completed	Age in years (average): 30		and week 6 (endpoint)	No significant difference at endpoint between the two
	Total study period: 6 weeks				groups ($P = 0.37$).
Kashani et al.	Study design:	Female outpatients who met	30 mg Saffron (petal) AND	Outcomes measured:	*Significance of reduction
(2013) ⁴⁵	Randomized, double blind,	DSM-IV criteria for major	40 mg Fluoxetine OR	Depression measured using	in HDRS score within
	placebo controlled	depression; were being	Placebo AND 40 mg	HDRS	groups for Saffron (coupled
	Country: Iran Sample size: 38 enrolled, 34 completed	treated with 40 mg / day of Fluoxetine for at least 6 weeks prior to entry; and, whose depressive symptoms had been stabilised (i.e. 50%	Fluoxetine	Outcomes measured at: Baseline, week 2 and week 4 (endpoint)	with Fluoxetine) and Placebo (coupled with Fluoxetine) from baseline to endpoint not recorded.

	Total study period: 4	reduction in depression			No significant difference at
	weeks	score)			endpoint between the two
		Age in years (average): 35			groups (<i>P</i> = 0.278).
Kell et al.	Study design:	Male and females self-	28 mg Saffron (stigma) OR	Outcomes measured:	The POMS Total Mood
(2017) ²⁸	Randomized, double blind,	reporting low mood but not	Saffron 22 mg (stigma)	Mood measured using	Disturbance score
	parallel group, placebo	diagnosed with depression	Saffron OR Placebo	POMS, Profile of Mood	significantly decreased for
	controlled	or another mood disorder		State; and, PANAS-21,	the 28 mg Saffron group
	Country: Australia	and who were otherwise		Positive and Negative	compared to Placebo at
		healthy		Affect Schedule	endpoint (<i>P</i> < 0.001). No
	Sample size: 128 enrolled,	Age in years (average): 39			treatment effect on the
	121 completed	rige in years (average).		Depression, anxiety and	POMS Total Mood
	Total study period: 4			stress measured using	Disturbance score for the
	weeks			DASS-21, Depression,	22mg Saffron group.
				Anxiety and Stress Scale	
					The PANAS-21 score for
				Outcomes measured at:	Positive Affect showed no
				Baseline and week 4	significant difference at
				(endpoint)	endpoint between the three





					both the 22 mg Saffron and
					Placebo groups at endpoint
					(P < 0.001 and P = 0.001,
					respectively).
Lopresti et al.	Study design:	Male and female youth who	14 mg Saffron (stigma) OR	Outcomes measured:	Youth reports: The total
$(2018)^{29}$	Randomized, double blind,	were assessed as suffering	Placebo	Depression and anxiety	RCADS score significantly
	placebo controlled	from mild-to-moderate		measured using youth and	decreased from baseline to
	Country: Australia	anxiety and depressive		parent reports for RCADS,	endpoint for the Saffron
		symptoms		Revised Child Anxiety and	group compared to Placebo
	Sample size: 80 enrolled,	A go in years (ayorago), 14		Depression Scale.	P < 0.049), and three
	68 completed Total study period: 8 weeks	Age in years (average): 14		Subscales: separation anxiety; generalised anxiety; panic; social phobia; obsessions/compulsions; depression	subscale scores: separation anxiety ($P = 0.003$); social phobia ($P = 0.023$); and, depression ($P = 0.016$). Parent reports: No significant difference from baseline to endpoint for total RCADS scores

				Outcomes measured at:	between groups ($P =$
				Baseline, week 2, week 4,	0.749). Saffron had a
				week 6 and week 8	significant mean
				(endpoint)	improvement ($P = 0.026$),
					and in two subscales from
					baseline to endpoint:
					generalised anxiety ($P <$
					0.01); and, obsessions/
					compulsions ($P < 0.01$).
Mazidi et al.	Study design:	Male and female patients	100 mg Saffron (stigma)	Outcomes measured:	The BDI and BAI scores
(2016) ⁴⁶	Randomized, double blind,	who met DSM-IV criteria	OR Placebo	Depression measured using	significantly decreased in
	placebo controlled	for mild-to-moderate mixed		BDI	the Saffron group compared
	Country: Iran	anxiety and depression			to Placebo from baseline to
	Country. Iran	based on the SCID-IV		Anxiety measured using	endpoint (<i>P</i> < 0.001).
	Sample size: 60 enrolled,			BAI	
	54 completed	Age in years (average): 43			

	Total study period: 12			Outcomes measured at:	
	weeks			Baseline, week 3, week 6,	
				and week 12 (endpoint).	
Moazen-	Study design:	Male and female patients	30 mg Saffron (stigma) OR	Outcomes measured:	No significant difference
Zadeh et al.	Randomized, double blind,	referred for on-pump	Placebo	Anxiety and Depression	from baseline to endpoint
(2017)47	placebo controlled	coronary artery bypass		measured using HADS,	for HADS anxiety and/or
	Country: Iran	grafting surgery with		Hospital Anxiety and	depression subscale scores
	country, num	WMS-R, Wechsler		Depression Scale	between Saffron and
	Sample size: 76 enrolled,	Memory Scale-Revised		Outcomes measured at:	Placebo groups ($P = 0.619$
	37 completed	score $>$ 70 and age $<$ 70.		Baseline and week 12	and $P = 0.208$,
	Total study period: 12	Enrolled to receive Saffron		(endpoint)	respectively).
	weeks	or Placebo from 2 days			
		before surgery up to 12			
		weeks after.			
		Age in years (average): 57			

Modabbernia	Study design:	Male patients who met	30 mg Saffron (stigma)	Outcomes measured:	No significant difference
et al. (2012) ⁴⁸	Randomized, double blind,	DSM-IV criteria for major	AND 40 mg Fluoxetine OR	Depression measured using	from baseline to endpoint
	placebo controlled	depressive disorder (MDD)	Placebo AND 40 mg	HDRS	for HDRS scores between
	Country: Iran Sample size: 36 enrolled, 30 completed Total study period: 4	and were currently being treated with Fluoxetine (40 mg / day for a minimum of 6 weeks prior to entry). Age in years (average): 38	Fluoxetine	Outcomes measured at: Baseline and week4 (endpoint)	Saffron (coupled with Fluoxetine) and Placebo (coupled with Fluoxetine) groups ($P = 0.178$).
	weeks				
Moshiri et al.	Study design:	Male and female	30 mg Saffron (petal) OR	Outcomes measured:	The HAM-D-17 score
(2006) ⁴⁹	Randomized, double blind,	outpatients who met DSM-	Placebo	Depression measured using	significantly decreased in
	placebo controlled	IV criteria for major		HAM-D-17	both the Saffron and
	Country: Iran Sample size: 40 enrolled, 36 completed	depression based on the SCID-IV, but were free of all psychiatric medication for at least 4 weeks prior to entry.		Outcomes measured at: Baseline, week 1, week 2, week 4 and week 6 (endpoint)	Placebo groups from baseline to endpoint (<i>P</i> < 0.001). However, the Saffron group had significantly lower HAM- D-17 scores at endpoint

	Total study period: 6	Age in years (average): 35			compared to Placebo ($P <$
	weeks				0.001)
Noorbala et	Study design:	Male and female	30 mg Saffron (stigma) OR	Outcomes measured:	The HAM-D-17 score
al. (2005) ²⁴	Randomized, double blind,	outpatients who met DSM-	20 mg Fluoxetine	Depression measured using	significantly decreased in
	parallel group	IV criteria for mild-to-		HAM-D-17	both the Saffron and
	Country: Iran	moderate depression based on the SCID-IV		Outcomes measured at: Baseline, week 1, week 2,	Fluoxetine groups from baseline to endpoint ($P <$
	Sample size: 40 enrolled,	Age in years (average): 36		week 4 and week 6	0.001). No significant
	38 completed	Age in years (average): 50			difference at endpoint
	Total study period: 6			(endpoint)	between the two groups (P
	weeks				= 0.71).
Sahraian et al.	Study design:	Male and female	30 mg Saffron (type not	Outcomes measured:	The BDI score significantly
(2016) ³¹	Randomized, double blind,	outpatients who met DSM-	recorded) AND 20 mg	Depression measured using	decreased in both the
	placebo controlled	IV criteria for major	Fluoxetine OR Placebo	BDI	Saffron (coupled with
	Country: Iran	depression based on the SCID-IV	AND 20 mg Fluoxetine		Fluoxetine) and Placebo (coupled with Fluoxetine)

	Sample size: 40 enrolled,	Age in years (average): 43		Outcomes measured at:	groups from baseline to
	30 completed			Baseline and week 4	endpoint ($P < 0.003$ and P
	Total study period: 4			(endpoint)	< 0.000. respectively). No
	weeks				significant difference at
					endpoint between the two
					groups ($P = 0.560$).
Shahmansouri	Study design:	Male and female	30 mg Saffron (stigma) OR	Outcomes measured:	The HDRS score
et al. (2013) ²⁵	Randomized, double blind,	outpatients who met DSM-	40 mg Fluoxetine	Depression measured using	significantly decreased in
	parallel group	IV criteria for mild-to-		HDRS	both the Saffron and
	Country: Iran	moderate depression based		Outcomes measured at:	Fluoxetine groups from
		on the SCID-IV and HDRS		Baseline, week 3 and week	baseline to endpoint. No
	Sample size: 44 enrolled,	scores of 14-22.		6 (endpoint)	significant difference at
	40 completed	Participants had also			endpoint between the two
	Total study period: 6	undergone Percutaneous			groups ($P = 0.70$).
	weeks	Coronary Intervention			
		(PCI) in the last 6 months			
		Age in years (average): 53			

Tabeshpour et	Study design:	Breastfeeding mothers with	30 mg Saffron (stigma) OR	Outcomes measured:	The BDI score significantly
al. (2017) ³⁰	Randomized, double blind,	mild-to-moderated	Placebo	Depression measured using	decreased in both the
	placebo controlled	depression based on		BDI-II	Saffron and Placebo groups
	Country: Iran Sample size: 78 enrolled, 60 completed Total study period: 8 weeks	"clinical interviews" Age in years (average): 36		Outcomes measured at: Baseline, week 4 and week 8 (endpoint)	from baseline to endpoint (P < 0.003 and P < 0.01, respectively). However, the Saffron group had significantly lower BDI scores at endpoint compared to Placebo ($P < 0.001$).
Talaei et al.	Study design:	Male and female	30 mg Saffron(crocin)	Outcomes measured:	The BDI and BAI scores
$(2015)^{32}$	Randomized, double blind,	outpatients who met DSM-	AND 20mg Fluoxetine; OR	Depression measured using	significantly decreased in
	placebo controlled	IV criteria for major	50mg Sertraline; OR 20mg	BDI	both groups from baseline
	Country: Iran Sample size: 46 enrolled, 40 completed	depression based on the SCID-IV Age in years (average): 36	Citalopram -OR-	Anxiety measured using BAI	to endpoint ($P < 0.0001$). However, the Saffron group had significantly lower BDI and BAI scores at endpoint

Total study period: 4	Placebo AND 20mg	Bipolar Disorder measured	compared to Placebo ($P <$
weeks	Fluoxetine; OR 50mg	using MDQ, Mood	0.0001).
	Sertraline; OR 20mg	Disorder Questionnaire	*Data for MDQ not
	Citalopram	Outcomes measured at:	reported
		Baseline and week 4	
		(endpoint)	

*Only outcomes of interest (e.g. depression and anxiety symptoms) were extracted and are presented.